Tracking the long-term safety and effectiveness of biologic and targeted synthetic therapies for psoriatic arthritis (PsA).
The PsA Register (BSR-PsA) provides 'real-world' data to assess the impact and natural history of psoriatic arthritis and response to treatments over the long-term.
The BSR-PsA was established in 2018 and is run by an expert team at the University of Aberdeen on behalf of the society. The register is aligned to other international registries with psoriatic arthritis patients in the EU and North America.
The register aims to provide 'real-world' data around:
- The impact of psoriatic arthritis on individuals, including function, work, quality of life and economic impact
- The natural history of psoriatic arthritis, including clinical, social and work outcomes in the medium- to long-term and the impact of disease phenotype on disease outcome
- The use of novel pharmacological agents (including biologic DMARDs, biosimilar DMARDs and targeted synthetic DMARDs), their use, effectiveness and predictors (including biomolecular predictors) of treatment response.
It also:
- Provides health economic data relevant to the evaluation of cost-effectiveness of different therapy options; and
- Provides infrastructure to support the collection, analysis and reporting of adverse events amongst patients on novel pharmacological agents.
If you're an NHS clinician, health professional or research network staff with a recruitment query about a patient or the treatment cohorts in PsA, please get in touch.
BSR and the University of Aberdeen are committed to ensuring that this rich dataset continues to drive impactful research and improved patient care. Access to the data is open, and applications are actively welcomed from anyone with an interest in using the registers to answer important clinical or research questions. The university registers team can work with researchers to develop and deliver research ideas.